Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

May’s top news stories

Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn, and The UK’s NHS has signed a managed access agreement to fund Biogen’s Spinraza for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA). wraps up key headlines from May 2019.


Go Top